US-based digital medicine developer Akili Interactive Labs has raised $30.5m in a funding round backed by healthcare research and development company PureTech Health.
The round also featured venture capital advisory firm Jazz Venture Partners and specialist investment fund Canepa Advanced Healthcare Fund.
Akili creates video games for mobile devices that improve cognitive function, targeting conditions such as paediatric attention deficit hyperactivity disorder, autism spectrum disorder, depression and traumatic brain injury.
The company also entered into a strategic collaboration agreement with pharmaceutical firm Pfizer in 2014 to explore applications for patients suffering from Alzheimer’s disease.
Akili’s lead product candidate, Project: Evo, is based on technology licensed from University of California, San Francisco.
The money will support further clinical development with a view to securing regulatory clearance in the US for a commercial launch in late 2017. The company is in the process of conducting several clinical trials of its platform.
Akili was co-founded by PureTech Health and several neuroscientists and games designers, and was incubated by the company’s PureTech Ventures unit.